Research & Development
Sepsis: Page 3
Bluejay Diagnostics completes clinical studies for sepsis triage
The Acton, MA-based firm said it will present the study results at the 2022 AACC Annual Scientific Meeting being held from July 26 to July 28 in Chicago.
July 5, 2022
Nanomix launches trial of eLab analyzer and panel
The company's eLab system is a mobile, handheld immunoassay and chemistry diagnostic system designed for rapid point-of-care testing, while the S1 Panel Cartridge was developed to aid in diagnosing critical infections, including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP), and lactate (LAC) from a single venous whole blood or plasma sample type.
June 22, 2022
Pathogenomix gets FDA designation for Patho-Seq assay
Patho-Seq was designed for the rapid detection and identification of hundreds of clinically relevant bacteria for a broad list of clinical conditions and sample types, including sepsis from whole blood samples and bacterial meningitis from cerebrospinal fluid, Pathogenomix said.
January 19, 2022
Immunexpress sepsis test gets FDA 510(k) clearance
SeptiCyte Rapid uses reverse transcription polymerase chain reaction to quantify directly from blood the relative expression of genes involved in a patient's immune response, the company said.
November 29, 2021
Prenosis gets $4.3M to develop sepsis test for U.S. military
Prenosis has developed an emergency point-of-care (ePOC) system, which builds upon its Immunix platform that uses machine-learning algorithms to identify sepsis as early as possible in hospitals. Now, the platform will be adapted for use on service members on the frontlines by replacing the standard large clinical lab analyzers with a mobile system.
November 16, 2021
Inflammatix wins $1.7M NIH grant
Using host immune mRNA signatures, the company has identified three sepsis subtypes ("endotypes"). The NIH award will allow Inflammatix to further investigate each endotype's signature and to develop a rapid, 30-minute test to identify them, it said.
November 14, 2021
Prenosis, Roche expand partnership to combat sepsis
The companies will build on a collaboration they began in 2020. Prenosis will significantly expand its core NOSIS dataset, a large and growing hybrid biomarker-clinical dataset for sepsis care. In addition, the two companies will work together to obtain U.S. Food and Drug Administration clearance for the Prenosis Sepsis Immunoscore and the Roche Elecsys IL-6 assay.
October 13, 2021
AAD secures BARDA contract for early sepsis detection test
QScout RLD+ can be used in urgent care clinics, doctor's offices, and other nonhospital settings, the company said. It is a rapid hematology analyzer that can describe a seven-part leukocyte differential, including quantifying band neutrophils and other immature granulocytes which can indicate severe infection. Results are available in two minutes compared to the two hours often required by a hospital's testing protocol, according to AAD.
October 5, 2021
Flu shots may protect against severe COVID-19
The annual flu shot may reduce the risks of stroke, sepsis, and deep vein thrombosis (DVT) in patients with COVID-19. Also, those who received influenza vaccines were significantly less likely to visit emergency departments and be admitted to intensive care units, according to the findings.
August 3, 2021
Ortho launches IL-6 reagent pack
Conditions that can be targeted by the test include autoimmune disorders, sepsis, severe respiratory infections from COVID-19, and community-acquired pneumonia in critically ill patients.
July 22, 2021
NanoDx inks deal with IBM, seeks EUA for COVID-19 test
Under the deal, NanoDx will get use of IBM's complementary metal oxide semiconductor (CMOS)-compatible nanoscale sensors to enhance and expand rapid testing for conditions such as sepsis, stroke, traumatic brain injury, and COVID-19.
July 13, 2021
CMS continues NTAP for T2's bacteria panel in FY 2021
The extension allows U.S. hospitals treating sepsis patients who are covered by Medicare to remain eligible for an NTAP of $97.50 for the T2Bacteria panel. This payment covers 65% of the average cost of the test panel, which detects pathogens that cause sepsis, for eligible patients, according to the company.
September 22, 2020
Page 3 of 5